Back

Prognostic Risk Refinement using Artificial Intelligence in HR+/HER2- Early Breast Cancer: Implications for CDK4/6 Eligibility Criteria

2026-01-25 oncology Title + abstract only
View on medRxiv
Show abstract

Patient selection and enrolment into phase III randomized clinical trials (RCTs) of adjuvant cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitor therapies depend on accurate risk definition. However, standard clinicopathologic criteria incompletely capture recurrence risk, limiting their efficacy in treatment selection. To assess whether artificial intelligence (AI)-enhanced prognostication may enrich the clinical risk groups utilized in the adjuvant NATALEE trial, we evaluated Ataraxis Breast RI...

Predicted journal destinations